The 15x Markup Hiding in Your IV Infusion Claims

The Line Item Nobody Questions

Every self-insured employer in Texas has IV infusion claims flowing through their plan. CPT 96374 — a therapeutic or diagnostic IV push of a single substance — is among the most common hospital outpatient billing codes in the country. It appears on claims for chemotherapy administration, antibiotic infusions, hydration therapy, iron infusions, and dozens of other treatments.

It is also one of the most mispriced procedures in commercial healthcare.

Our analysis of 1,660 negotiated rate records across 5 Houston-area facilities reveals a pricing pattern that most employers never see: a 15-to-1 spread between the highest and lowest payer median rates for the identical service. The median across all payers is $142 — approximately 4.7 times the Medicare reimbursement. But that median conceals dramatic variation that directly impacts your plan's bottom line.

The Payer-by-Payer Reality

When we disaggregate the IV push rates by payer, the pattern becomes clear. This is not random variation. It is a structured pricing disparity that persists across every major commercial payer operating in Houston:

• Humana: $322 median negotiated rate
• United Healthcare: $160
• Aetna: $143
• Blue Cross Blue Shield: $123
• Oscar Health: $90
• Cigna: $88
• Community Health Choice: $51
• Centene: $21

Humana's median rate is 15 times Centene's. Both networks include overlapping Houston facilities. The drug being pushed, the nursing time, the IV supplies, and the monitoring requirements are identical regardless of which insurance card the patient presents. Yet the negotiated price ranges from $21 to $322.

For a Benefits Director reviewing aggregate claims data, these individual line items are invisible. They are buried in facility charges, bundled with drug costs, and obscured by the complexity of hospital billing. But they compound.

The Compounding Effect

A single IV push at $322 versus $21 is a $301 difference. That sounds manageable until you consider the math at scale.

IV infusion and push codes rarely appear in isolation. A typical outpatient infusion visit generates multiple line items: an initial infusion hour (96365), additional hours (96366), sequential infusions (96367), concurrent infusions (96368), and one or more IV pushes (96374, 96375, 96376). Our Houston data shows similar pricing patterns across the entire infusion code family:

• 96360 (IV infusion, hydration, first hour): median $152, range $37-$365
• 96361 (IV infusion, hydration, additional hour): median $39, range $6-$158
• 96365 (IV infusion, therapeutic, first hour): median $129, range $32-$364
• 96375 (IV push, each additional substance): median $116, range $38-$379

The Medicare ratio across these codes ranges from 2.5x to 10x. Every code in the family shows the same pattern: wide payer-to-payer variation, with the highest-cost payer paying 5-15 times what the lowest-cost payer pays.

For an employer with 2,000 covered lives, infusion-related claims might represent 200-400 claim events per year. If your plan's negotiated rates sit in the upper quartile rather than the lower quartile, the annual excess spend on infusion services alone can reach $150,000-$300,000. This is money leaving your plan for no clinical benefit.

Why This Happens

Three structural factors drive infusion pricing disparity:

1. Site-of-Care Arbitrage

The same IV push administered in a hospital outpatient department costs dramatically more than one administered in a physician's office or freestanding infusion center. Hospital outpatient departments add facility fees — charges for the overhead of operating within a hospital campus — that can double or triple the total cost of the service.

Our data captures rates negotiated at hospital-based facilities, where the majority of commercially insured infusions occur. But the clinical service itself does not require a hospital setting. Many infusion therapies — including most IV antibiotics, iron infusions, and hydration treatments — can be safely administered in lower-cost ambulatory settings.

The persistence of hospital-based infusion is not driven by clinical necessity. It is driven by referral patterns, patient convenience, and the fact that most plan designs do not create meaningful incentives for site-of-care selection.

2. Opacity in Contract Structure

Infusion codes are rarely negotiated individually. They are typically part of a broad fee schedule that covers thousands of CPT codes, often expressed as a percentage of billed charges or a multiplier of Medicare rates. This means the specific rate for CPT 96374 is a byproduct of the overall contract structure, not a deliberate pricing decision.

This is precisely why the variation is so wide. No one is looking at the individual rate. The TPA reports a blended discount percentage. The broker reports a network savings number. Neither metric reveals that your plan is paying $322 for a service that another payer in the same market has negotiated at $21.

3. Information Asymmetry

Until the Transparency in Coverage Rule forced payers to publish their negotiated rates, employers had no way to benchmark their plan's pricing against the broader market. Even now, the data is published in formats that are difficult to analyze without specialized infrastructure.

The result is a market where price information flows freely among hospitals and payers — who use it to calibrate their negotiations — but remains opaque to the employers who ultimately pay the bills. This asymmetry is the root cause of the 15x spread we observe in the Houston infusion data.

What Smart Employers Are Doing

The employers who are capturing savings from infusion pricing share three characteristics:

Infusion Site-of-Care Programs

The highest-impact intervention is redirecting appropriate infusion services from hospital outpatient departments to freestanding infusion centers or home infusion providers. Studies consistently show 30-50% cost reductions with equivalent or better clinical outcomes and patient satisfaction.

This requires three things: a plan design that creates cost incentives for lower-cost settings, a prior authorization framework that identifies candidates for site-of-care steering, and a communication strategy that helps employees understand the benefit.

Rate-Level Benchmarking

Rather than relying on aggregate discount metrics, leading employers are benchmarking their negotiated rates at the CPT-code level against market percentiles and Medicare multiples. This analysis identifies the specific codes where their plan is overpaying — and quantifies the savings opportunity with precision.

For infusion codes, this benchmarking often reveals that a plan's overall discount percentage is masking significant overpayment on specific high-volume services. A plan might achieve a respectable 45% average discount while still paying 75th-percentile rates on infusion codes that represent material claim volume.

Contract Renegotiation with Data

Armed with rate-level benchmarking, employers enter contract negotiations with their TPA or payer from a position of information parity. Rather than debating discount percentages, the conversation shifts to specific rates: "Our plan is paying $322 for CPT 96374 at Houston Methodist. The market median is $142. Centene has negotiated $21 at the same facilities. We need this rate at or below the 25th percentile."

This is a fundamentally different negotiation than "we need a better discount." It is specific, defensible, and difficult to deflect.

Quantifying Your Exposure

The infusion pricing pattern in Houston is not unique to Houston. Our data shows similar spreads across Texas metro areas where we have sufficient coverage. What makes infusion pricing particularly impactful is the combination of high volume, wide price variation, and available lower-cost alternatives.

For a self-insured employer evaluating their plan's infusion exposure, the analysis is straightforward:

1. Pull infusion-related claims (CPT 96360-96376) from your past 12 months of claims data
2. Identify the volume and total spend — this is often larger than employers expect
3. Benchmark each code against market rates — where does your plan sit on the percentile distribution?
4. Calculate the gap between your current rates and the 25th percentile for your metro
5. Estimate site-of-care savings — what percentage of your infusion claims could be redirected to lower-cost settings?

The typical self-insured employer with 2,000 covered lives discovers $200,000-$500,000 in addressable infusion spend through this analysis. The savings from rate optimization and site-of-care steering combined can reduce that spend by 30-50%.

The data is there. The question is whether anyone is looking at it.